Choice of combined oral contraception for adolescent girls and young women
Objective. To carry out a systematic analysis of the data available in the literature on the use of combined oral contraceptives (COCs) by adolescent girls and young women.Kuznetsova I.V.
Material and methods. Foreign and Russian articles published in the past 15 years were sought in the international citation database Pubmed for their analysis.
Results. The paper highlights the factors influencing adherence to COC use in adolescent girls and young women (a fear of complications and side effects, the lack of responsibility in young women, a low level of awareness of the benefits and risks of hormonal contraception). It is shown that after adequate medical consultation, the use of COC by adolescent girls and young women can offer additional health and quality of life benefits.
Conclusion. The correct choice of a dosage regimen and hormonal components in the composition of COCs is a guarantee for adherence to contraception in young female users. COCs containing drospirenone and a microdose of ethinyl estradiol (a 24/4 regimen) are one of the most attractive combinations for most adolescent girls and young women today.
Keywords
contraception
combined oral contraceptives
adolescent girls
drospirenone
noncontraceptive effects
References
1. Sabatini R., Orsini G., Cagiano R., Loverro G. Noncontraceptive benefits of two combined oral contraceptives with antiandrogenic properties among adolescents. Contraception. 2007; 76: 342-7.
2. Уварова Е.В., Спиридонова Н.В., Казакова А.В. Взаимосвязь знаний о контрацепции и применение ее среди девочек-подростков средних специальных учреждений г. Самары. Репродуктивное здоровье детей и подростков. 2016; 3: 85-95. [Uvarova E.V., Spiridonova N.V., Kazakova A.V. Interrelation of knowledge about contraception and its application among teenage girls of secondary special institutions in Samara. Reproduktivnoe zdorove detey i podrostkov. 2016; 3: 85-95. (in Russian)]
3. Chernick L.S., Schnall R., Higgins T., Stockwell M., Castaño P., Santelli J., Dayan P.S. Barriers to and Enablers of Contraceptive Use among Adolescent Females and their Interest in an Emergency Department-based Intervention. Contraception. 2015; 91(3): 217-25.
4. Negriff S., Dorn L.D., Hillman J.B., Huang B. The measurement of menstrual symptoms: Factor structure of the menstrual symptom questionnaire in adolescent girls. J. Health Psychol. 2009; 14(7): 899-908.
5. Герасимова Л.И., Денисов М.С., Шувалова Н.В. Репродуктивное здоровье девушек студенток как медико-социальная проблема. Современные проблемы науки и образования. 2015; 6. [Gerasimova L.I., Denisov M.S., Shuvalova N.V. Reproductive health of female students as a medical and social problem. Sovremennyie problemyi nauki i obrazovaniya. 2015; 6. (in Russian)]
6. Lynn D.D., Umari T., Dunnick C.A., Dellavalle R.P. The epidemiology of acne vulgaris in late adolescence. Adolesc. Health Med. Ther. 2016;7: 13-25.
7. Trussell J. Understanding contraceptive failure. Best Pract. Res. Clin. Obstet. Gynaecol. 2009; 23: 199-209.
8. Дикке Г.Б., Ерофеева Л.В. Контрацепция в современной России: применение и информированность (популяционное исследование). Акушерство и гинекология. 2016; 2: 108-13. https://dx.doi.org/10.18565/aig.2016.2.108-113 [Dikke G.B., Erofeeva L.V. Contraception in Russia today: Use and awareness (A population-based study). Akusherstvo i ginekologiya/Obstetrics and Gynecology. 2016; (2): 108-13. (in Russian) https://dx.doi.org/10.18565/aig.2016.2.108-113]
9. Lindh I., Blohm F., Andersson-Ellström E., Milsom I. Contraceptive use and pregnancy outcome in three generations of Swedish female teenagers from the same urban population. Contraception. 2009; 80(2): 163-9.
10. Lawrie T.A., Helmerhorst F.M., Maitra N.K., Kulier R., Bloemenkamp K., Gülmezoglu A.M. Types of progestogens in combined oral contraception: effectiveness and side-effects. Cochrane Database Syst. Rev. 2011; (5): CD004861.
11. Dinger J.C., Bardenheuer K., Assmann A. International Active Surveillance Study of Women Taking Oral Contraceptives (INAS-OC Study). BMC Med. Res. Methodol. 2009; 9: 77.
12. Dinger J., Minh T.D., Buttmann N., Bardenheuer K. Effectiveness of oral contraceptive pills in a large U.S. cohort comparing progestogen and regimen. Obstet. Gynecol. 2011; 117(1): 33-40.
13. Dinger J. Comparative effectiveness of combined oral contraceptives in adolescents. J. Fam. Plann. Reprod. Health Care. 2011; 37: 118.
14. Chaiyasit N., Taneepanichskul S. A study of cycle control, side effects and client's satisfaction of a low dose combined contraceptive containing ethinylestradiol/drospirenone (24/4 regimen). J. Med. Assoc. Thai. 2010; 93(5): 517-22.
15. Lidegaard Ø., Nielsen L.H., Skovlund Ch.W., Skjeldestad F.E., Løkkegaard E. Risk of venous thromboembolism from use of oral contraceptives containing different progestogens and oestrogen doses: Danish cohort study, 2001-9. BMJ. 2011; 343: d6423.
16. Medical eligibility criteria for contraceptive use. 5th ed. Geneva: WHO; 2015. 267p.
17. Westhoff C., Jones K., Robilotto C., Heartwell S., Edwards Sh., Zieman M., Cushman L. Smoking and oral contraceptive continuation. Contraception. 2009; 79(5): 375-8.
18. Nelson A. New low-dose, extended-cycle pills with levonorgestrel and ethinyl estradiol: an evolutionary step in birth control. Int. J. Womens Health. 2010; 2: 99-106.
19. Klipping C., Duijkers I., Fortier M.P., Marr J., Trummer D., Elliesen J. Long-term tolerability of ethinylestradiol 20 µg/drospirenone 3 mg in a flexible extended regimen: results from a randomised, controlled, multicentre study. J. Fam. Plann. Reprod. Health Care. 2012; 38(2): 84-93.
20. Gallo M.F., Lopez L.M., Grimes D.A., Carayon F., Schulz K.F., Helmerhorst F.M. Combination contraceptives: effects on weight. Cochrane Database Syst. Rev. 2014; (1): CD003987.
21. Sitruk-Ware R., Nath A. Characteristics and metabolic effects of estrogen and progestins contained in oral contraceptive pills. Best Pract. Res. Clin. Endocrinol. Metab. 2013; 27(1): 13-24.
22. Lopez L.M., Grimes D.A., Schulz K.F. Steroidal contraceptives: effect on carbohydrate metabolism in women without diabetes mellitus. Cochrane Database Syst. Rev. 2012; (4): CD006133.
23. Conway G., Dewailly D., Diamanti-Kandarakis E., Escobar-Morreale H.F., Franks S., Gambineri A. et al. The polycystic ovary syndrome: a position statement from the European Society of Endocrinology. Eur. J. Endocrinol. 2014; 171(4): P1-29.
24. Lemay A., Poulin Y. Oral contraceptives as anti-androgenic treatment of acne. J. Obstet. Gynaecol. Can. 2007; 24(7): 559-67.
25. Caprio M., Antelmi A., Chetrite G., Muscat A., Mammi C., Marzolla V. et al. Antiadipogenic effects of the mineralocorticoid receptor antagonist drospirenone: potential implications for the treatment of metabolic syndrome. Endocrinology. 2011; 152(1): 113-25.
26. Bertolini S., Elicio N., Cordera R., Gapitanio G.L., Montagna G., Croce S. et al. Effects of three low-dose oral contraceptive formulations on lipid metabolism. Acta Obstet. Gynecol. Scand. 2007; 66(4): 327-32.
27. Javed A., Kashyap R., Lteif A.N. Hyperandrogenism in female athletes with functional hypothalamic amenorrhea: a distinct phenotype. Int. J. Womens Health. 2015; 7: 103-11.
28. Naessén S., Carlström K., Byström B., Pierre Y., Hirschberg A.L. Effects of antiandrogenic oral contraceptive on appetite and eating behavior in bulimic women. Psychoneuroendocrinology. 2007; 32(5): 548-54.
29. Елесина И.Г., Чеботарева Ю.Ю. Некоторые аспекты репродуктивных нарушений при первичной олигоменорее у девушек-подростков. Репродуктивное здоровье детей и подростков. 2016; 3: 22-3. [Elesina I.G., Chebotareva Yu.Yu. Some aspects of reproductive disorders in primary oligomenorrhea in adolescent girls. Reproduktivnoe zdorove detey i podrostkov. 2016; 3: 22-3. (in Russian)]
30. Tan J.K., Ediriweera C. Efficacy and safety of combined ethinyl еstradiol/drospirenone oral contraceptives in the treatment of acne. Int. J. Womens Health. 2009; 1: 213-21.
31. Arowojolu A.O., Gallo M.F., Lopez L.M., Grimes D.A. Combined oral contraceptive pills for treatment of acne. Cochrane Database Syst. Rev. 2012; (7): CD004425.
32. Breech L.L., Braverman P.K. Safety, efficacy, actions, and patient acceptability of drospirenone/ethinyl estradiol contraceptive pills in the treatment of premenstrual dysphoric disorder. Int. J. Womens Health. 2009; 1: 85-95.
33. Ткаченко Л.В., Хамад Н.П., Яхонтова М.А. Особенности клиники предменструального синдрома у молодых женщин. Репродуктивное здоровье детей и подростков. 2016; 3: 54-5. [Tkachenko L.V., Hamad N.P., Yakhontova M.A. Features of the clinic of premenstrual syndrome in young women. Reproduktivnoe zdorove detey i podrostkov. 2016; 3: 54-5. (in Russian)]
34. Прилепская В.Н., Межевитинова Е.А., Сасунова Р.А., Иванова Е.В., Летуновская А.Б., Набиева К.Р. Результаты клинического применения препарата, содержащего дроспиренон, у женщин с тяжелой формой предменструального синдрома. Акушерство и гинекология. 2012; 2: 81-5. [Prilepskaya V.N., Mezhevitinova E.A., Sasunova R.A., Ivanova E.V., Letunovskaya A.B., Nabiyeva K.R. Results of the clinical use of a drospirenone-containing agent in women with severe premenstrual syndrome. Akusherstvo i ginekologiya/Obstetrics and Gynecology. 2012; 2: 81-5. (in Russian)]
35. Wichianpitaya J., Taneepanichskul S. A comparative efficacy of low-dose combined oral contraceptives containing desogestrel and drospirenone in premenstrual symptoms. Obstet. Gynecol. Int. 2013; 2013:487143.
36. Bitzer J., Paoletti A.M. Added benefits and user satisfaction with a low-dose oral contraceptive containing drospirenone: results of three multicenter trials. Clin. Drug Invest. 2009; 29(2): 73-8.
37. Josefsson A., Wiréhn A.-B., Lindberg M., Foldemo A., Brynhildsen J. Continuation rates of oral hormonal contraceptives in a cohort of first-time users: a population-based registry study, Sweden 2005–2010. BMJ Open. 2013; 3(10): e003401.
38. Hooper D.J. Attitudes, awareness, compliance and preferences among hormonal contraception users: A global, cross-sectional, self-administrated, online survey. Clin. Drug Investig. 2010; 30(11): 749-63.
Received 08.12.2017
Accepted 22.12.2017
About the Authors
Irina Vsevolodovna Kuznetsova, MD, professor of the Department of Obstetrics and Gynecology No. 1, Therapeutic Faculty, I.M. Sechenov First Moscow State Medical University. 119992, Russia, Moscow, Malaya Trubetskaya str. 8, bld. 2For citations: Kuznetsova I.V. Choice of combined oral contraception for adolescent girls and young women. Akusherstvo i Ginekologiya/Obstetrics and Gynecology. 2018; (1): 35-40. (in Russian)
https://dx.doi.org/10.18565/aig.2018.1.35-40
Similar Articles
